IS5008A - C-peptíð insúlíns - Google Patents

C-peptíð insúlíns

Info

Publication number: IS5008A
Authority: IS; Iceland
Prior art keywords: peptides; atpase activity; peptide; fragment; sequence
Prior art date: 1996-09-27

Application number

IS5008A

Other languages

English (en)

Inventor

Wahren John

Johansson Bo-Lennart

Jörnvall Hans

Original Assignee

Creative Peptides Sweden Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-27

Filing date

1999-03-23

Publication date

1999-03-23

1999-03-23 Application filed by Creative Peptides Sweden Ab filed Critical Creative Peptides Sweden Ab

1999-03-23 Publication of IS5008A publication Critical patent/IS5008A/is

Links

VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 4
102000004196 processed proteins & peptides Human genes 0.000 abstract 4
108091006112 ATPases Proteins 0.000 abstract 3
102000057290 Adenosine Triphosphatases Human genes 0.000 abstract 3
230000000694 effects Effects 0.000 abstract 3
239000012634 fragment Substances 0.000 abstract 3
208000002249 Diabetes Complications Diseases 0.000 abstract 2
108010075254 C-Peptide Proteins 0.000 abstract 1
206010012655 Diabetic complications Diseases 0.000 abstract 1
101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
230000003592 biomimetic effect Effects 0.000 abstract 1
230000001413 cellular effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000001747 exhibiting effect Effects 0.000 abstract 1
210000002950 fibroblast Anatomy 0.000 abstract 1
108010038088 glutamyl-glycyl-seryl-leucyl-glutamine Proteins 0.000 abstract 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
150000002894 organic compounds Chemical class 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1
210000005233 tubule cell Anatomy 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)

IS5008A 1996-09-27 1999-03-23 C-peptíð insúlíns IS5008A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9603533A SE520392C2 (sv)	1996-09-27	1996-09-27	Specifika peptider för behandling av diabetes mellitus
PCT/GB1997/002627 WO1998013384A1 (en)	1996-09-27	1997-09-26	Insulin c-peptides

Publications (1)

Publication Number	Publication Date
IS5008A true IS5008A (is)	1999-03-23

Family

ID=20404052

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS5008A IS5008A (is)	1996-09-27	1999-03-23	C-peptíð insúlíns

Country Status (24)

Country	Link
US (1)	US6610649B2 (is)
EP (1)	EP0938503B1 (is)
JP (1)	JP2001500893A (is)
KR (1)	KR20000048643A (is)
AT (1)	ATE347562T1 (is)
AU (1)	AU741901B2 (is)
BG (1)	BG103362A (is)
BR (1)	BR9711573A (is)
CA (1)	CA2266416C (is)
CZ (1)	CZ108599A3 (is)
DE (1)	DE69737065T2 (is)
DK (1)	DK0938503T3 (is)
ES (1)	ES2278394T3 (is)
HU (1)	HUP0000432A3 (is)
IL (1)	IL129143A0 (is)
IS (1)	IS5008A (is)
NO (1)	NO991483L (is)
NZ (1)	NZ335231A (is)
PL (1)	PL332494A1 (is)
RU (1)	RU2206336C2 (is)
SE (1)	SE520392C2 (is)
SK (1)	SK39499A3 (is)
TR (1)	TR199900694T2 (is)
WO (1)	WO1998013384A1 (is)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0022342D0 (en) *	2000-09-12	2000-10-25	Creative Peptides Sweden Ab	Reduction of the electrocardiographic QT interval
DE10055857A1 (de) *	2000-11-10	2002-08-22	Creative Peptides Sweden Ab Dj	Neue pharmazeutische Depotformulierung
US20030198666A1 (en) *	2002-01-07	2003-10-23	Richat Abbas	Oral insulin therapy
JP5452843B2 (ja) *	2003-01-06	2014-03-26	エミスフィアーテクノロジーズインコーポレイテッド	夜間の経口インスリン治療
US20050026826A1 (en) *	2003-01-17	2005-02-03	Margarethe Hoenig	Feline proinsulin, insulin and constituent peptides
US20050203001A1 (en) *	2004-03-05	2005-09-15	Emisphere Technologies, Inc.	Oral insulin therapies and protocol
GB0323979D0 (en)	2003-10-13	2003-11-19	Creative Peptides Sweden Ab	Therapeutic applications for c-peptide
EP1753446A4 (en) *	2004-05-27	2009-10-28	Essential Skincare Llc	ALPHA-1 GLYCOPROTEIN ACID FOR THE TREATMENT OF DIABETES
US7833513B2 (en)	2004-12-03	2010-11-16	Rhode Island Hospital	Treatment of Alzheimer's Disease
GB0601950D0 (en) *	2006-01-31	2006-03-15	Creative Peptides Sweden Ab	Compositions and methods of treating diabetes
EP2054437A2 (en) *	2006-08-07	2009-05-06	Teva Biopharmaceuticals USA, Inc.	Albumin-insulin fusion proteins
US20100292132A1 (en) *	2007-09-11	2010-11-18	Dorian Bevec	Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent
GB0723250D0 (en) *	2007-11-28	2008-01-09	Univ Leeds	Compositions and methods for reducing macrovascular complications in diabetic patients
US20110165112A1 (en) *	2008-09-19	2011-07-07	Nektar Therapeutics	Polymer conjugates of c-peptides
AU2009292643B2 (en)	2008-09-19	2016-02-18	Nektar Therapeutics	Polymer conjugates of therapeutic peptides
US8410049B2 (en) *	2009-10-28	2013-04-02	Cebix	Methods and kits for preventing hypoglycemia
CA2798518A1 (en)	2010-05-17	2011-11-24	Cebix, Inc.	Pegylated c-peptide
EP2683393B1 (en)	2011-02-11	2018-04-11	The Regents of The University of Michigan	Tripeptide compositions and their use for treatment of diabetes
EP2780030A4 (en)	2011-11-17	2015-11-18	Cebix Ab	PEGYLATED C-PEPTIDE
RU2522897C1 (ru) *	2013-04-16	2014-07-20	Закрытое акционерное общество "ФАРМ-ХОЛДИНГ"	Твердая кишечнорастворимая лекарственная форма с-пептида проинсулина для перорального применения (варианты) и способ ее получения (варианты)
KR101676542B1 (ko) *	2014-12-30	2016-11-16	건국대학교 산학협력단	프로인슐린의 면역학적 용도
CN104888201B (zh) *	2015-06-29	2018-04-27	齐锦生	用于防治糖尿病及其慢性并发症的肽类药物
EP4421088A3 (en)	2017-02-06	2024-12-04	Uit de Krempe IP B.V.	C-peptide's interaction with elastin receptor, a blueprint for understanding vascular disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU166913B (is) *	1972-05-15	1975-06-28
JPS5210872B2 (is) *	1973-07-14	1977-03-26
JPS55105653A (en) *	1978-10-02	1980-08-13	Shionogi & Co Ltd	Tyrosyl c-peptides
CA1176158A (en)	1981-08-27	1984-10-16	Ronald E. Chance	Pharmaceutical formulations comprising human insulin and human c-peptide
US4652548A (en) *	1981-08-27	1987-03-24	Eli Lilly And Company	Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
DE3326473A1 (de)	1983-07-22	1985-01-31	Hoechst Ag, 6230 Frankfurt	Pharmazeutisches mittel zur behandlung des diabetes mellitus
US4581165A (en)	1984-06-14	1986-04-08	Eli Lilly And Company	Anti-diabetic compounds
US5104854A (en)	1989-02-01	1992-04-14	Washington University	Antiviral peptides
IL93282A (en)	1989-02-09	1995-08-31	Lilly Co Eli	Insulin analogues
US5364757A (en)	1990-05-21	1994-11-15	Administrators Of The Tulane Educational Fund	Methods of supporting a diagnosis of systemic lupus erythematosus
IL99699A (en) *	1990-10-10	2002-04-21	Autoimmune Inc	Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
JPH05268982A (ja)	1992-03-27	1993-10-19	Hoechst Japan Ltd	骨形成作用を有する新規な蛋白質およびその製造法
ES2142867T3 (es)	1992-04-13	2000-05-01	Oklahoma Med Res Found	Procedimientos y reactivos para el diagnostico de autoanticuerpos.
WO1994025071A1 (en)	1993-05-05	1994-11-10	Keith Rose	Polyoxime compounds and their preparation
AT400723B (de)	1993-08-27	1996-03-25	Biomay Prod & Handel	Rekombinante alternaria alternata allergene
CN1157621A (zh)	1994-07-08	1997-08-20	达特茅斯大学理事会	用于检测和治疗i型糖尿病的胰岛素原肽化合物
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9422175D0 (en)	1994-11-03	1994-12-21	Univ Dundee	Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
GB9509164D0 (en)	1995-05-05	1995-06-28	Smithkline Beecham Plc	Novel compounds
BR9708082A (pt)	1996-03-15	1999-07-27	Corixa Corp	Compostos e métodos para a imunoterapia e imunodiagnose de câncer de próstata
US6150500A (en)	1996-07-12	2000-11-21	Salerno; John C.	Activators of endothelial nitric oxide synthase

1996
- 1996-09-27 SE SE9603533A patent/SE520392C2/sv not_active IP Right Cessation
1997
- 1997-09-26 EP EP97942119A patent/EP0938503B1/en not_active Expired - Lifetime
- 1997-09-26 DE DE69737065T patent/DE69737065T2/de not_active Expired - Lifetime
- 1997-09-26 JP JP10515410A patent/JP2001500893A/ja not_active Ceased
- 1997-09-26 KR KR1019990702585A patent/KR20000048643A/ko not_active Withdrawn
- 1997-09-26 TR TR1999/00694T patent/TR199900694T2/xx unknown
- 1997-09-26 CA CA002266416A patent/CA2266416C/en not_active Expired - Fee Related
- 1997-09-26 CZ CZ991085A patent/CZ108599A3/cs unknown
- 1997-09-26 WO PCT/GB1997/002627 patent/WO1998013384A1/en not_active Ceased
- 1997-09-26 AU AU43915/97A patent/AU741901B2/en not_active Ceased
- 1997-09-26 IL IL12914397A patent/IL129143A0/xx unknown
- 1997-09-26 RU RU99108434/14A patent/RU2206336C2/ru not_active IP Right Cessation
- 1997-09-26 DK DK97942119T patent/DK0938503T3/da active
- 1997-09-26 HU HU0000432A patent/HUP0000432A3/hu unknown
- 1997-09-26 PL PL97332494A patent/PL332494A1/xx unknown
- 1997-09-26 NZ NZ335231A patent/NZ335231A/xx unknown
- 1997-09-26 US US09/269,439 patent/US6610649B2/en not_active Expired - Fee Related
- 1997-09-26 AT AT97942119T patent/ATE347562T1/de not_active IP Right Cessation
- 1997-09-26 SK SK394-99A patent/SK39499A3/sk unknown
- 1997-09-26 ES ES97942119T patent/ES2278394T3/es not_active Expired - Lifetime
- 1997-09-26 BR BR9711573-8A patent/BR9711573A/pt not_active Application Discontinuation
1999
- 1999-03-23 IS IS5008A patent/IS5008A/is unknown
- 1999-03-26 NO NO991483A patent/NO991483L/no not_active Application Discontinuation
- 1999-04-27 BG BG103362A patent/BG103362A/xx unknown

Also Published As

Publication number	Publication date
DE69737065T2 (de)	2007-06-28
HUP0000432A2 (hu)	2000-08-28
TR199900694T2 (xx)	1999-06-21
DK0938503T3 (da)	2007-04-10
SK39499A3 (en)	1999-10-08
SE9603533L (sv)	1998-03-28
ATE347562T1 (de)	2006-12-15
BG103362A (en)	2000-05-31
EP0938503B1 (en)	2006-12-06
AU4391597A (en)	1998-04-17
IL129143A0 (en)	2000-02-17
NO991483D0 (no)	1999-03-26
SE9603533D0 (sv)	1996-09-27
AU741901B2 (en)	2001-12-13
CA2266416C (en)	2008-04-29
DE69737065D1 (en)	2007-01-18
SE520392C2 (sv)	2003-07-01
US20020107175A1 (en)	2002-08-08
CA2266416A1 (en)	1998-04-02
RU2206336C2 (ru)	2003-06-20
JP2001500893A (ja)	2001-01-23
PL332494A1 (en)	1999-09-13
NO991483L (no)	1999-05-18
NZ335231A (en)	2000-11-24
HUP0000432A3 (en)	2000-10-30
ES2278394T3 (es)	2007-08-01
EP0938503A1 (en)	1999-09-01
US6610649B2 (en)	2003-08-26
BR9711573A (pt)	2000-01-18
CZ108599A3 (cs)	1999-08-11
WO1998013384A1 (en)	1998-04-02
KR20000048643A (ko)	2000-07-25

Publication	Publication Date	Title
IS5008A (is)	1999-03-23	C-peptíð insúlíns
PT699686E (pt)	2004-02-27	Fragmentos de peptido insulinotropico do tipo glucagona biologicamente activos
PT1171465E (pt)	2004-12-31	Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes
BR9711098B1 (pt)	2011-10-04	compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
DE69710095D1 (de)	2002-03-14	Pharmazeutische zubereitung zur behandlung von diabetes
TR199901971T2 (xx)	1999-12-21	Bir resept�re ba�lanan peptidler ve bile�ikler.
TR200100600T2 (tr)	2001-07-23	İnsülinotropik peptitlerin kullanımı.
DE3578611D1 (de)	1990-08-16	Instrumente zur behandlung von verformten naegeln bei menschlichen patienten.
PT1033990E (pt)	2002-07-31	21-hidroxi-6,19-oxidoprogesterona (21oh-6op) e a sua utilizacao como medicamento para tratar o excesso de glucocorticoides
ATE304371T1 (de)	2005-09-15	Verwendung von staphylococcus enterotoxin homologe für krebs-therapie
IS4510A (is)	1997-06-19	Peptíð p277 hliðstæður og lyfjasamsetningar sem innihalda þær, til meðhöndlunar eða sjúkdómsgreiningar á sykursýki
BR9105783A (pt)	1992-07-21	Polipeptidio,processo para o tratamento em vidro de neuronios e composicoes celular e farmaceutica
WO1999064598A3 (de)	2000-03-16	Neue insulinanaloga mit erhöhter zinkbindung
ES2059457T3 (es)	1994-11-16	Utilizacion de bezafibrato para el tratamiento de la diabetes.
DE50009838D1 (de)	2005-04-28	Humanes antibiotisches protein
DE69120390D1 (de)	1996-07-25	Kollagen-bindendes protein sowie dessen herstellung
WO2001007479A3 (en)	2001-08-23	Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
ATA103997A (de)	2001-12-15	Wässerige zusammensetzung zum vorgerben von hautblössen oder nachgerben von leder
ATE206306T1 (de)	2001-10-15	Verwendung von 9,10-secocholesta-5,7,10(19)-trien-1,3-ol (alfacalcidol)
WO2003099863A3 (en)	2004-02-19	Resistin binding proteins, their preparation and use
DK1340507T3 (da)	2005-02-28	Anvendelse af et fibroblastvækstfaktor-bindingsprotein til behandling og diagnosticering af diabetiske sårhelingsforstyrrelser
BR9703451A (pt)	1998-12-22	Composto natural para tratamento de diabete câncer e etc
ATE57088T1 (de)	1990-10-15	Transkutaner nagel zur fixierung von knochenfragmenten oder -teilen.
DE69002383D1 (de)	1993-09-02	Zusammensetzung zur heilung von autoimmunkrankheiten.